| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Q3 2026 net revenue of $35.3 million; ZYNRELEF® net revenue up 13.8% and APONVIE® net revenue up 49.3% compared to the third quarter of 2025 |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +1 more
CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. |
| 29 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 23, 2026 (the “Effective Date”), Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a multi-product Development and License Agreement (the “License Agreement”) with Long Grove Pharmaceuticals, LLC... |
| 14 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders
This Amendment No. 1 to Tax Benefit Preservation Plan (this “Amendment”) is dated as of August 13, 2026 (the “Effective Date”), and amends that certain Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Plan”), by and betwe... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year |
| 25 Jun 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On June 25, 2026, Heron Therapeutics, Inc. (the “Company”) received a written notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying it that the closing bid price of the Company’... |
| 16 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Heron Therapeutics, Inc. (the “Company”) held on June 11, 2026, the Company’s stockholders voted on six proposals, including: (1) to elect seven director nominees: Crai... |
| 02 Jun 2026 |
8-K: Other Events
— After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal — |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%) |
| 06 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of April 3, 2026 (the “Effective Date”), by and between HERON THERAPEUTICS, INC. (the “Company”), and CRAIG COLLARD (the “Executive”).... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
CARY, N.C., Jan. 9, 2026 — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 million |
| 29 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cu... |
| 15 Oct 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the Special Stockholders’ Meeting (the “Special Meeting”)of Heron Therapeutics, Inc. (the “Company”) held on October 13, 2025, the Company’s stockholders voted on two proposals, including: (1) to approve, pursuant to Nasdaq Listing Ru... |
| 28 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Office Lease Agreement (the “Lease”), dated as of August 22, 2025, with USEF HCG Fenton LLC, a Delaware limited liability company (the “Landlord”). The Lea... |
| 15 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more
Tax Benefit Preservation Plan, dated as of August 14, 2025 (this “Plan”), between Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company N.A., a limited liability trust company, as Rights Agent ... |
| 12 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. |
| 12 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
On August 6, 2025, Heron Therapeutics, Inc. (the “Company”) entered into a Framework Agreement (the “Framework Agreement”) with Patheon Austria GmbH & Co KG (“Patheon”) and Thermo Fisher Scientific Inc. (solely for purposes as specified ... |
| 08 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more
Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million |
Loading...